| Name | Title | Contact Details |
|---|---|---|
Suresh Namala |
Executive Director, IT Risk and Compliance | Profile |
Amino acid biology is fundamental to life, regulating biological pathways critical to health. A variety of conditions occur when amino acid pathways become dysregulated.
Agrivida is developing and commercializing solutions that are the next evolutionary step in animal nutrition, using the plant as a factory to produce and deliver highly differentiated products. We are transforming the economics of enzyme and animal feed production through our use of plant-expressed enzymes and plant modification to develop transformational products for monogastric and ruminant animal nutrition.
Loyal is part of Cellular Longevity, a company working to develop the first drugs explicitly intended to extend healthspan and lifespan — first in dogs, and then in humans, too. By quantifying and controlling the mechanisms of aging, we hope to delay the onset and reduce the severity of age-related diseases, which means more, healthier years for both species. At Loyal, our first products to market are focused on longevity and healthspan in dogs. Join us in our mission to help dogs everywhere.
Virtual Incision Corporation is a privately-held medical device company focused on developing an advanced, miniaturized robot for general surgery abdominal procedures, such as colon resections. Propelled by the knowledge that colorectal and lower gastrointestinal procedures are the fastest growing in the United States, Dr. Dmitry Oleynikov and Dr. Shane Farritor founded Virtual Incision in 2006. The company is a spin-out of the University of Nebraska, where Dr. Dmitry Oleynikov and Dr. Shane Farritor are currently based. John Murphy joined Virtual Incision in 2012 and is based in Pleasanton, California.
Vivodyne accelerates the successful discovery, design, and development of human therapeutics through the convergence of novel biology, robotics, and AI. Our platform enables customers to massively de-risk drug candidates by testing them against functional, lab-grown, human organs and multi-organ systems. We conduct preclinical discovery and clinical development campaigns to generate new therapeutic strategies from these proprietary, physiologically-realistic organs at unprecedented scale, speed, and quality through automation and machine learning. We`re financially backed by some of the most selective and successful venture funds, and several “Top 10” global pharmaceutical innovators have already partnered with us to expand, strengthen, and accelerate their therapeutic pipelines.